Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Loma Linda University Eye Institute, Loma Linda, California Midwest Cornea Associates, LLC, Carmel, Indiana Francis Price Jr, MD, Indianapolis, Indiana Minnesota Eye Consultants, Minnetonka, Minnesota Legacy Devers Eye Institute, Portland, Oregon Stuart A. Terry, MD PA, San Antonio, Texas